+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy



ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy



Asian Pacific Journal of Cancer Prevention 18(2): 507-513



Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic

(PDF emailed within 0-6 h: $19.90)

Accession: 059692846

Download citation: RISBibTeXText

PMID: 28345838

DOI: 10.22034/APJCP.2017.18.2.507


Related references

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. Oncotarget 6(40): 43135-43143, 2016

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Investigation 28(2): 172-180, 2010

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology 22(4): 848-856, 2011

Prolonged clinical benefit from platinum-based chemotherapy in a patient with metastatic triple negative breast cancer. European Journal of Gynaecological Oncology 30(4): 449-451, 2009

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. Journal of Translational Medicine 12: 272, 2016

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biology and Therapy 18(6): 369-378, 2017

Platinum-based chemotherapy in metastatic triple negative breast cancer: Experience of a tertiary referral centre in India. Gulf Journal of Oncology 1(17): 52-57, 2015

Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy. Magyar Onkologia 55(2): 105-109, 2011

Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. Journal of Clinical Oncology 26(15_suppl): 1008-1008, 2016

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncology Letters 7(3): 866-870, 2014

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. Tumour Biology 35(9): 8721-8731, 2014

Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. Tumour Biology 35(12): 12255-12263, 2015

Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs. Zhonghua Zhong Liu Za Zhi 36(10): 788-792, 2015

Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. European Journal of Cancer 48(18): 3378-3385, 2013

Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pacific Journal of Cancer Prevention 15(6): 2591-2596, 2015